Advinus Therapeutics Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Advinus Therapeutics Ltd - Product Pipeline Review - 2016', provides an overview of the Advinus Therapeutics Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Advinus Therapeutics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Advinus Therapeutics Ltd - The report provides overview of Advinus Therapeutics Ltd including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Advinus Therapeutics Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Advinus Therapeutics Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Advinus Therapeutics Ltd's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Advinus Therapeutics Ltd - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Advinus Therapeutics Ltd's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Advinus Therapeutics Ltd Snapshot 6 Advinus Therapeutics Ltd Overview 6 Key Information 6 Key Facts 6 Advinus Therapeutics Ltd - Research and Development Overview 7 Key Therapeutic Areas 7 Advinus Therapeutics Ltd - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Advinus Therapeutics Ltd - Pipeline Products Glance 14 Advinus Therapeutics Ltd - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Advinus Therapeutics Ltd - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Advinus Therapeutics Ltd - Drug Profiles 17 GKM-001 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Small Molecule for Type 2 Diabetes 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 PNQ-103 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PNQ-201 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PNQ-370 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PNQ-849 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule for Visceral Leishmaniasis 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PNQ-154 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 PNQ-401 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PNQ-701 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule for Leishmaniasis 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecule to Antagonize GPR40 for Obesity 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Advinus Therapeutics Ltd - Pipeline Analysis 34 Advinus Therapeutics Ltd - Pipeline Products by Target 34 Advinus Therapeutics Ltd - Pipeline Products by Route of Administration 35 Advinus Therapeutics Ltd - Pipeline Products by Molecule Type 36 Advinus Therapeutics Ltd - Pipeline Products by Mechanism of Action 37 Advinus Therapeutics Ltd - Recent Pipeline Updates 38 Advinus Therapeutics Ltd - Dormant Projects 39 Advinus Therapeutics Ltd - Locations And Subsidiaries 40 Head Office 40 Other Locations & Subsidiaries 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Advinus Therapeutics Ltd, Key Information 6 Advinus Therapeutics Ltd, Key Facts 6 Advinus Therapeutics Ltd - Pipeline by Indication, 2016 8 Advinus Therapeutics Ltd - Pipeline by Stage of Development, 2016 10 Advinus Therapeutics Ltd - Monotherapy Products in Pipeline, 2016 11 Advinus Therapeutics Ltd - Partnered Products in Pipeline, 2016 12 Advinus Therapeutics Ltd - Partnered Products/ Combination Treatment Modalities, 2016 13 Advinus Therapeutics Ltd - Phase II, 2016 14 Advinus Therapeutics Ltd - Preclinical, 2016 15 Advinus Therapeutics Ltd - Discovery, 2016 16 Advinus Therapeutics Ltd - Pipeline by Target, 2016 34 Advinus Therapeutics Ltd - Pipeline by Route of Administration, 2016 35 Advinus Therapeutics Ltd - Pipeline by Molecule Type, 2016 36 Advinus Therapeutics Ltd - Pipeline Products by Mechanism of Action, 2016 37 Advinus Therapeutics Ltd - Recent Pipeline Updates, 2016 38 Advinus Therapeutics Ltd - Dormant Developmental Projects,2016 39 Advinus Therapeutics Ltd, Other Locations 40
List of Figures
Advinus Therapeutics Ltd - Pipeline by Top 10 Indication, 2016 8 Advinus Therapeutics Ltd - Pipeline by Stage of Development, 2016 10 Advinus Therapeutics Ltd - Monotherapy Products in Pipeline, 2016 11 Advinus Therapeutics Ltd - Partnered Products in Pipeline, 2016 12 Advinus Therapeutics Ltd - Pipeline by Top 10 Target, 2016 34 Advinus Therapeutics Ltd - Pipeline by Route of Administration, 2016 35 Advinus Therapeutics Ltd - Pipeline by Molecule Type, 2016 36 Advinus Therapeutics Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016 37
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.